Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
A legfontosabb adatok
- Hol
- Brussels, Charleroi, Leuven és Saint-Servais (Belgium)Mind a 4 helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan embereket keres, akik hordozzák a Huntington-kór génváltozását, valamint rokonokat és más, a génváltozást nem hordozó személyeket kontrollcsoportnak.
- Életkor
- 18 éves kortól; 18 év alattiak is részt vehetnek, ha juvenilis kezdetű Huntington-kórjuk van.
- Nem
- Mindkét nem részt vehet.
- A betegség stádiuma
- A HD génváltozás hordozói, egyértelmű betegségtünetekkel vagy anélkül (manifeszt vagy premanifeszt). Egyes csoportok nem hordozzák a génváltozást.
- Biomarker vagy leletérték
- A HD gén expanziós mutációjának hordozása, vagy annak hiánya (kontrollok); a rokonok génállapota ismeretlen is lehet.
A részvétel fő kizáró okai
- Akik nem felelnek meg a bevonási feltételeknek
- Koreás mozgászavarral élők, ha a HD génmutáció tesztje negatív
- Kontrollként jelentkezők, akiknek súlyos központi idegrendszeri betegségük van, például agyvérzés, Parkinson-kór vagy sclerosis multiplex
Gépi kiolvasás: 2026. november 12.
Helyszínek itt: Belgium
- Bruxelles - ErasmeBrussels, BelgiumContact: Nick AlaertsRésztvevőt keres
- Institut de Pathologie et de Génétique (IPG)Charleroi, BelgiumContact: Cécile MinetRésztvevőt keres
- University Hospitals LeuvenLeuven, BelgiumContact: Ann-Julie TrippasRésztvevőt keres
- Hôpital du Beau Vallon ASBLSaint-Servais, BelgiumContact: Jean-Marie WarzeeRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- CHDI Foundation, Inc.
- Azonosító
- NCT01574053
- A regiszteradat frissítve
- 2024. február 28.
- Eredeti leírás
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.A teljes eredeti leírásKevesebb
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
Bevonási feltételek: Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation; Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation; These two major categories can be further subdivided into six different subgroups of eligible individuals:; Manifest/Motor-manifest HD: Carriers with clinical features that are regarded in the opinion of the investigator as diagnostic of HD; Pre-Manifest/-Motor-manifest HD: Carriers without clinical features regarded as diagnostic of HD; Genotype Unknown: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has not undergone predictive testing for HD and therefore has an undetermined carrier status; Genotype Negative: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has undergone predictive testing for HD and is known not to carry the HD expansion mutation; Family Control: Family members or individuals not related by blood to carriers (e.g., spouses, partners, caregivers); Community Controls: Individuals unrelated to HD carriers who did not grow up in a family affected by HD. Data collected from community controls will be used for generation of normative data for sub-studies; Participant status will be captured in the study database using 2 variables: 1) Investigator Determined Status: this will be based on clinical signs and symptoms and genotyping performed as part of medical care, and will be updated at every visit; and 2) Research Genotyping Status: this will be based on genotyping conducted as part of Enroll-HD study procedures. Based on research genotyping, participants will be reclassified under this variable from Genotype Unknown to 'Carriers' or 'Controls'. Investigators and participants will be blinded to this reclassification.
Kizáró feltételek: Individuals with choreic movement disorders in the context of a negative test for the HD gene mutation; For Community Controls: those individuals with a major central nervous system disorder will be excluded (e.g. stroke, Parkinson's disease, multiple sclerosis, etc.); Participants under 18 may be eligible to participate (if they have juvenile-onset HD); Individuals who do not meet inclusion criteria,.